WMS 2023 infographic: Connecting the dots: All-around care and evidence in Duchenne muscular dystrophy
The PTC Therapeutics ‘Connecting the dots’ symposium at WMS 2023 provided an overview of the latest clinical and real-world evidence in nonsense mutation Duchenne muscular dystrophy (nmDMD), and highlighted the importance of continuity in all-around care. This infographic from the symposium summarizes the key evidence presented
Appreciate the benefits of lifetime use of corticosteroids in DMD
Get up to date with the latest phase 3 clinical data for ataluren use in nmDMD
Discover the key real-world data on how ataluren delays disease milestones vs standard of care in nmDMD
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This infographic was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300195 | December 2023
Sign in or register to access exclusive content on this site